Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases

Journal of Nuclear Medicine

Volumn 53, Issue 9, 2012, Pages 1345-1351

  Muralidharan, Vijayaragavan ^a   Kwok, Marco ^a   Lee, Sze Ting ^a   Lau, Lawrence ^a   Scott, Andrew M ^a   Christophi, Christopher ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

18F FDG PET CT; Colorectal liver metastases; MTV; Prognostic scoring system; TGV

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GLUCOSE; IRINOTECAN; OXALIPLATIN; DIAGNOSTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; LIVER RESECTION; LUNG METASTASIS; LUNG RESECTION; MALE; METASTASIS; METASTASIS RESECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GLYCOLYSIS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; SURVIVAL; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84866178185     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.102749     Document Type: Article

References (29)

1. Garcia M, Jemal A, Ward E, et al. Global Cancer Facts & Figures 2007: American Cancer Society. 2007.
2. Primrose JN. Surgery for colorectal liver metastases. Br J Cancer. 2010;102: 1313-1318.
3. Malafosse R, Penna C, Sa Cunha A, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 2001;12:887-894.
4. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999.
5. Doci R, Gennari L, Bignami P, et al. Morbidity and mortality after hepatic resection of metastases from colorectal cancer. Br J Surg. 1995;82:377-381.
6. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:318-321.
7. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291-299.
8. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-1262.
9. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-135.
10. Merkel S, Bialecki D, Meyer T, Muller V, Papadopoulos T, Hohenberger W. Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J Surg Oncol. 2009;100:349-357.
11. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007;246:183-191.
12. Neal CP, Garcea G, Doucas H, et al. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. Eur J Cancer. 2006;42:1728-1743.
13. Scott AM, Gunawardana DH, Kelley B, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1451-1457.
14. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-3260.
15. 18F]-D-glucose. Cancer. 1998;82:2227-2234.
16. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907-1911.
17. Chatterton BE, Ho Shon I, Baldey A, et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:354-361.
18. 18F-FDG PET scans. J Nucl Med. 2007;48:1449-1458.
19. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
20. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-856.
21. Maithel SK, Gonen M, Ito H, et al. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery. 2012;151:162-170.
22. Reissfelder C, Rahbari NN, Koch M, et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16:3279-3288.
23. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328-333.
24. 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115-122.
25. de Geus-Oei LF, Wiering B, Krabbe PF, Ruers TJ, Punt CJ, Oyen WJ. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol. 2006;17:1650-1655.
26. Cheebsumon P, van Velden FH, Yaqub M, et al. Measurement of metabolic tumor volume: static versus dynamic FDG scans. EJNMMI Res. 2011;1:35.
27. 18F-FDG PET/CT scan correlation. J Med Imaging Radiat Oncol. 2011;55:320-332.
28. Tanaka K, Shimada H, Miura M, et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg. 2004;28:263-270.
29. 18f-fluoromisonidazole. Semin Nucl Med. 2007;37:451-461.